TiGenix NV - Euronext Brussels: TIG.BR
We are an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of stem cells to develop novel therapies for serious medical conditions.
Our current therapeutic focus is inflammatory, autoimmune and cardiac diseases, which we target through products developed from our two proprietary platforms of adipose-derived (eASC) and cardiac stem cells (CSC).
Both platforms use allogeneic (donor derived) stem cells, which allow the development of off-the-shelf products.
TiGenix NV was incorporated in the year 2000.
In 2011, TiGenix acquired Cellerix SL in Spain, shifting its focus to the development of allogeneic stem cell therapies and creating the basis for what the company is today.